Dr. Cheng Huang 黄诚
Chief Physician
Department of Thoracic Medical Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology focusing on chemotherapy and the diagnosis and treatment of lung cancer and esophageal cancer.
Dr. Huang graduated from Fujian Medical University in 1980. As Director of Internal Medicine, Dr. Huang has long specialized in tumor chemotherapy. Dr. Huang has participated in multiple international multicenter clinical studies, published over 50 academic papers in core journals, and received one provincial-level scientific and technological achievement award.
Professional roles
- Standing Committee Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Member, Cancer Rehabilitation and Palliative Care Professional Committee, China Anti-Cancer Association
- Executive Committee Member (3rd Term), Chinese Society of Clinical Oncology (CSCO)
- Chair, Fujian Provincial Lung Cancer Professional Committee
Name order: in Chinese the family name comes first (Huang Cheng). Papers usually list the name as Cheng Huang or Huang C.
Selected publications
42 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Natl Compr Canc Netw, 2026 (senior author): Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial. PubMed 42119607
- J Natl Compr Canc Netw, 2022 (senior author): Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial. PubMed 36075387
- J Natl Compr Canc Netw, 2021 (senior author): Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial. PubMed 34343968
- Oncologist, 2020 (senior author): Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial. PubMed 32533785
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion